Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Altogen Biosystems, Thermo Fisher Scientific

Premium
Invitrogen has introduced two new RNAi research vectors.
 
The first, Block-iT HiPerform Lentiviral Pol-II miR RNAi expression system with Emerald Green Fluorescent Protein, can be used to deliver to non-dividing, primary, and hard-to-transfect cells, Invitrogen said.
 
The second, Block-iT Inducible Pol-II miR RNAi expression system, uses a tetracycline-inducible promoter that allows researchers to control RNAi expression.
 

 
Altogen Biosystems has introduced new contract research services for RNAi including transfection services, assay development and library screening, cloning and vector construction, stable cell-line generation, and RNAi and gene-targeting experiments.
 

 
Thermo Fisher Scientific has introduced the Dharmacon Accell siRNA, a novel form of siRNA that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses, or electroporation.
 
According to the company, the siRNA can silence genes in all cell types tested to date when mixed with the optimized Accell delivery media and added to cultured cells.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.